Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
OBJECTIVE
It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and North-American algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment.


METHODS
The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed.


RESULTS
A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed.


CONCLUSIONS
The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment.
Department of Neurology, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil. alessandro.finkels@gmail.com
Alessandro
A
Finkelsztejn
Alberto Alain
AA
Gabbai
Yara Dadalti
YD
Fragoso
Adriana
A
Carrá
Miguel Angel
MA
Macías-Islas
Raul
R
Arcega-Revilla
Juan
J
García-Bonitto
Carlos Luis
CL
Oehninger-Gatti
Geraldine
G
Orozco-Escobar
Adriana
A
Tarulla
Fernando
F
Vergara
Darwin
D
Vizcarra
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000465:Algorithms; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007843:Latin America; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D060735:Pharmacovigilance
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents